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ABSTRACT
Purpose: To investigate plasma lutein (L) and zeaxanthin (Z) concentrations with grading-confirmed and
self-reported prevalence of age-related macular degeneration (AMD).
Material and methods: Data collected from a nationally representative prospective cohort study of
community-dwelling adults aged 50 years and over in the Republic of Ireland. Participants underwent
a computer-assisted personal interview and a center-based health assessment. Plasma concentrations of
L and total Z (Z and meso-zeaxanthin [MZ]) were measured by high performance liquid chromatography,
and retinal photographs were graded using a version of the AMD International Classification and
Grading System. Consumption of supplements containing L and/or Z and/or MZ was recorded as
supplement use. Four groups were identified: Group 1 (n = 24): AMD-afflicted and correctly aware;
Group 2 (n = 264): AMD-afflicted but unaware; Group 3 (n = 41): AMD-free and incorrectly believed that
they were afflicted with the condition; Group 4 (n = 4094): AMD-free and correctly self-reported absence
of AMD.
Results: Of 4,423 participants with plasma concentrations of L and Z and gradable retinal photographs,
288 (6.5%) were afflicted with AMD, and 65 (1.5%) self-reported AMD. Controlling for family history and
age, the relationship between grading-confirmed AMD and plasma L was positive and significant
(p < 0.001). Mean plasma concentrations of L in Group 2 (mean = 0.2162 ± 0.132 µmol) and Group 4
(mean = 0.2040 ± 0.121 µmol/L) were significantly lower than Group 1 (mean = 0.4691 ± 0.0.372 µmol/L)
and Group 3 (mean = 0.3176 ± 0.0.235 µmol/L). Supplement use was reported by 41.7% and 17.1% of
participants in Groups 1 and 3, respectively, but only 2.7% and 1.9% of participants in Groups 2 and 4,
respectively.
Conclusion: A belief that one suffers from AMD, whether justified or not, is associated with supplement
use and with higher plasma concentrations of L.
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Introduction
The macula, a specialized area of the retina, mediates
central and color vision.1 Age-related macular degenera-
tion (AMD) is a disease of the macula that, in its
advanced stage, results in the loss of central vision if
untreated or if untreatable.2 Early (non-advanced) AMD
is characterized by drusen and/or pigmentary abnormal-
ities; whereas, the late (advanced) form of AMD is visually
consequential and can be classified as atrophic (geographic
atrophy or dry) or neovascular (choroidal neovasculariza-
tion or wet).3 AMD is the leading cause of irreversible
blindness in the older population, especially in developed
countries.4 We have recently shown that the overall pre-
valence of any form of AMD (i.e. early or advanced) in
adults aged 50 years or older in the Republic of Ireland
(ROI) is 7.2% (census-weighted).5 The incidence and pre-
valence of AMD will continue to rise because of increasing
longevity and because of the growing world population.6
The global projection of people with AMD is estimated at
196 million by 2020, further increasing to 288 million by
2040.7
The loss of central vision in patients afflicted with
AMD has a dramatic and adverse impact on their quality
of life.8 For example, the impact of vision loss associated
with AMD may result in an inability to drive, to read, to
recognize faces, or to watch television, with a consequen-
tial loss of social independence and increasing need for
family support,9 which is a major concern in the context
of an advancing population. The financial burden of vision
loss and/or impairment may be classed as direct or
indirect.10 The indirect costs include the loss of the
patient’s income, the cost of care-givers, nursing homes
and other costs (e.g. transport, etc.).10 Direct costs include
hospital care, outpatient and office visits, optometry costs,
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drugs and other direct expenses.10 Currently, there is no
effective treatment for atrophic AMD, whereas neovascu-
lar AMD is treated by intravitreal injections of anti-vas-
cular endothelial growth factor (anti-VEGF) therapy,
which has been shown to dramatically reduce the risk of
vision loss,11 but at an average annual cost per eye per
year of $24,000.12
Established risk factors for AMD include increasing age,
family history of disease (genetic background), and tobacco
use; whereas, exposure to short-wavelength (blue) light, obe-
sity, cardiovascular disease and diet (antioxidant status) are
described as putative risk factors for this condition.13
Although the etiopathogenesis of AMD remains elusive, we
now know that oxidative stress is a key factor in the develop-
ment of this disease.14,15 Indeed, and over the last few dec-
ades, there has been a growing body of research investigating
the protective role of carotenoids for AMD,16 which culmi-
nated in the publication of the Age-Related Eye Disease Study
(AREDS) 2 in 2013.17,18 Specifically, it has been demonstrated
that supplementation with at least two of the three macular
carotenoids (lutein [L], zeaxanthin [Z]) in association with co-
antioxidants (vitamin C, vitamin E, zinc, and copper) reduces
the risk of progression from intermediate AMD to advanced
AMD.17,18 Moreover, a recent double-blind, randomized clin-
ical trial reported that, in patients with early AMD, supple-
mentation with all three of macular pigment’s constituent
carotenoids in a meso-zeaxanthin [MZ]:L:Z (mg) ratio of
10:10:2 enhances visual performance and is non-inferior (in
terms of macular pigment augmentation) to the AREDS 2
formulation.19 Interestingly, carotenoids are entirely of dietary
origin and, therefore, their concentration in plasma and con-
sequential bioavailability for uptake by the retina is dependent
on consumption of foods containing these nutrients (such as
leafy greens and colored fruits and vegetables) or
supplements.
The association between plasma concentrations of L and
Z with diet, age, ethnicity, and AMD status has been pre-
viously reported.20–23 However, the current investigation,
conducted as part of the Irish Longitudinal Study on
Ageing (TILDA) study, see below, is the first population-
based study to report on the relationship between plasma
concentrations of L and Z and grading-confirmed AMD
while investigating the impact of self-reporting of AMD,
supplement use and plasma concentrations of the relevant
carotenoids.
Materials and methods
Study design
TILDA is a nationally representative, longitudinal study of the
health, economic and social status of 8,175 adults aged 50 years
and over in the ROI. The design and methodology of TILDA
are described in detail elsewhere.24 In brief, a nationally repre-
sentative sample of community-dwelling adults was drawn from
the Irish Geodirectory, a comprehensive record of all residential
addresses in the ROI. Addresses were selected by means of
RANSAM (a random sampling design for the ROI) using a
three stage process where all household residents aged
50 years or older were eligible to participate.24
Participants
Wave 1 consisted of three separate components: (1) a face-to-
face interview using a computer assisted personal interview
(CAPI); (2) a self-completion questionnaire (SCQ); 3) a health
assessment carried out in either a dedicated health center
(based in Dublin and Cork) or, alternatively, a modified
assessment was carried out in the participant’s own home if
he/she was unable/unwilling to travel to the health center.
Retinal photographs were not obtained from participants
who opted not to attend a health center assessment
(n = 3,140). Wave 1 health assessment had an overall response
rate of 62% (i.e. 62% of 8,175 = 5035). Figure 1 illustrates
TILDA participants included in this investigation.
This study was approved by the Faculty of Health Sciences
Research Ethics Committee of Trinity College Dublin and the
local Ethics Committee at the Waterford Institute of
Technology. All participants provided signed informed con-
sent prior to enrolment in the study. The study was conducted
in accordance with the tenets of the Declaration of Helsinki
regarding research into human volunteers.
Interview
Participants completed a CAPI, which was carried out by a
trained social interviewer.24 Participants were asked whether,
to their knowledge, a doctor’s diagnosis of AMD had been
made in their individual case and, whether, to their knowl-
edge, there was a family history of AMD. A list of medica-
tions, including food supplements consumed on a daily basis,
was recorded for each participant. The exact wording of the
question was as follows: “MD001: Now I would like to record
all medications that you take on a regular basis, like every day
or every week. This will include prescription and non-pre-
scription medications, over-the-counter medicines, vitamins,
and herbal and alternative medicines.” For the purpose of the
current analysis, information on supplements that contained
at least one of the three constituent carotenoids of macular
pigments (i.e. either L and/or Z and/or MZ) was also
recorded, and this was then coded as yes or no (and hence-
forth referred to as supplement use).
Retinal photographs
All retinal photography was performed by TILDA nurses, who
were trained and certified by experts from the Ocular
Epidemiology Reading Centre at the University of Wisconsin,
Madison, USA. One 45° monoscopic color photograph, cen-
tered on the macula (EDTRS standard field 2) was obtained for
each eye using the NIDEK AFCE-210 non-mydriatic auto-fun-
dus camera through a non-dilated pupil. Pupil dilation was not
feasible for this large study, given that participants had to
undergo many other tests, some of which would have been
adversely influenced by pupil dilation (e.g. gait assessment).
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AMD grading
Retinal photographs were graded using a modified version of
the International Classification and Grading System for
AMD.5 Early (non-advanced) AMD was defined as the pre-
sence of more than 10 hard drusen (< 63 µm) and/or the
presence of soft drusen (>125 µm). Late (advanced) AMD was
defined as the presence of atrophic AMD and/or neovascu-
lar AMD.
Plasma L and Z assessment
The TILDA protocol for non-fasting venous blood sample
collection, processing and storage has been described
previously.25 In summary, 1 ml of plasma wrapped in tinfoil
was stored at −80°C and dedicated to carotenoid assessment.
L and total Z (zeaxanthin and meso-zeaxanthin) was analyzed
using a reversed phase high performance liquid chromatogra-
phy (HPLC) method. Details of the extraction procedures and
HPLC analysis that we used have been previously described.26
Statistical analysis
The statistical package IBM SPSS Statistics for Windows
Version 22.0 was used for analysis. In an earlier report of
this TILDA cohort,5 we found that AMD prevalence was
linked to age and family history of AMD. In the current
analysis, we investigated the respective relationships between
self-reported AMD (justified and unjustified), use of supple-
ments containing at least one of the three macular carotenoids
and mean plasma concentrations of L and Z. The statistical
methods employed included contingency table analysis and
post hoc analysis of variance. Accordingly, and along with
plasma concentrations of L and Z, we incorporated these
variables into our logistic regression models for this current
study. However, we did not incorporate other variables, such
as sex, education, BMI, and so on, as these were not found to
be significantly related to AMD in the earlier report of this
cohort.5 The 5% level of significance was used throughout,
without adjustment for multiple testing.
Results
Demographic, health and lifestyle characteristics for the 4,423
TILDA participants reported herein are presented in Table 1.
The participants’ mean age was 61 ± 8 years; and 231 parti-
cipants (5.2%) reported a family history of AMD. 288 parti-
cipants (6.5%) exhibited signs of early or late AMD (early
AMD: n = 273; 6.2%; late AMD: n = 15; 0.34%;). Because of
the small numbers of cases of late AMD, cases of early (non-
advanced) and late AMD were combined in subsequent ana-
lyses (and henceforth referred to as AMD). As previously
reported in this sample,5 increasing age and a positive family
history of AMD were strongly associated with prevalence
of AMD.
Using logistic regression, the association between grading-
confirmed AMD and plasma concentrations of L and Z, in
each case controlling for age and family history of AMD, were
investigated. The relationship between AMD and plasma L
Wave 1 (baseline) TILDA participants
N = 108 participants with ungradable 
retinal photographs 
N = 504 participants did not have
plasma lutein and zeaxanthin 
analysed
8175 TILDA participants
completed interview
3140 TILDA participants did not 
undergo a center-based health 
assessment (i.e. no retinal 
photograph)
4423 TILDA participants eligible
for analysis
5035 TILDA participants who 
underwent a center-based health 
assessment
Figure 1. The Irish Longitudinal Study on Ageing (TILDA) participants included in this investigation. Photographs were judged as ungradable based on a priori criteria
of photographic quality. The phenomenon of participants without plasma concentration of lutein and zeaxanthin was attributable to one of the following: participant
did not consent to give a blood sample, a failure to perform a venepuncture at the time of the health assessment, insufficient sample for carotenoid analysis or
sample lost during carotenoid extraction/analysis.
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was positive and highly significant (p < 0.001), demonstrating
that AMD is associated with higher plasma concentrations of
L in this cohort. There was no significant relationship between
plasma concentration of Z and AMD (p > 0.05).
This unexpected association between AMD and plasma
concentrations of L prompted us to explore whether self-
reported family history of AMD and/or self-report of AMD
(whether justified or not) were associated with use of supple-
ments containing at least one of the three macular carote-
noids, which in turn might have contributed to our
observations. In our study cohort, 231 participants (5.2%)
reported a family history of AMD and 102 participants
(2.3%) reported use of supplements containing at least one
of the three macular carotenoids (supplement use). A small
number of participants (n = 65; 1.5%) believed that they were
afflicted with AMD on the basis of a doctor’s diagnosis,
whereas 4,358 participants (98.5%) reported that they were
not afflicted with this condition. Subsequent AMD grading,
however, revealed that not all of these self-reports were accu-
rate, and that we had, in fact, four distinct subject groups in
our study: Group 1 (n = 24): grading-confirmed AMD in
association with justified self-report of AMD (i.e. grading
positive/self-report positive); Group 2 (n = 264): grading-
confirmed AMD in participants who were unaware that they
suffer from AMD (i.e. grading positive/self-report negative);
Group 3 (n = 41): grading-confirmed absence of AMD in
participants who (incorrectly) self-reported AMD (i.e. grading
negative/self-report positive); Group 4 (n = 4,094): grading-
confirmed absence of AMD in participants who justifiably
reported that they were not afflicted with AMD (i.e. grading
negative/self-report negative).
We used post hoc analysis of variance (Tukey HSD) to
investigate plasma concentrations of L and Z in these four
groups. Plasma concentrations of L in Group 2 (grading
positive/self-report negative; mean = 0.2162 ± 0.132 µmol/
L;) and Group 4 (grading negative/self-report negative;
mean = 0.2040 ± 0.121 µmol/L;) were found to be significantly
lower than in Group 1 (grading positive/self-report positive;
mean = 0.4691 ± 0.0.372 µmol/L; p < 0.001 and p < 0.001,
respectively) and Group 3 (grading negative/self-report posi-
tive; mean = 0.3176 ± 0.0.235 µmol/L; p < 0.001and p < 0.001,
respectively) as shown in Figure 2.
Plasma concentrations of Z in Group 1 (grading positive/self-
report positive; mean = 0.1101 ± 0.105 µmol/L;) were significantly
greater than in Group 2 (grading positive/self-report negative;
mean = 0.0551 ± 0.041 µmol/L; p < 0.05), Group 3 (grading
negative/self-report positive; mean = 0.0735 ± 0.069 µmol/L;
p < 0.001) and Group 4 (grading negative/self-report negative;
mean = 0.0557 ± 0.046 µmol/L; p < 0.001) (Figure 2).
The role of other variables that might have influenced the
observed relationships between a grading-confirmed diagnosis
of AMD and plasma concentrations of L were also investi-
gated, including use of supplements containing at least one of
the three macular carotenoids (supplement use) and factors
that might have prompted the use of such supplements (i.e.
family history of AMD and/or self-report of AMD).
Supplement use was found to be significantly higher in parti-
cipants who self-reported AMD (whether justified or unjusti-
fied); 41.7% and 17.1% of participants in Groups 1 and 3,
respectively, were using a supplement containing at least one
of the three macular carotenoids, and this compares with only
2.7% and 1.9% of Groups 2 and 4, respectively (p < 0.001,
Pearson Chi-Square). Similarly, 9.1% of participants who self-
reported a family history of AMD reported use of a supple-
ment containing at least one of the three macular carotenoids,
compared with just 1.9% who did not report a family history
of AMD (p < 0.001, Pearson Chi-Square).
Discussion
The principal and novel finding in this population-based
study was that participants who believed that they suffer
from AMD (and irrespective of whether this belief is founded
or unfounded) exhibit higher plasma concentrations of L than
participants who do not believe they suffer from this condi-
tion (again, irrespective of whether this latter belief is justified
or unjustified). Our findings have profound implications for
epidemiologic studies investigating the prevalence of, and risk
factors for, AMD; moreover, our findings also inform the
debate regarding the appropriateness of introducing a screen-
ing program for non-advanced AMD.
In this report, plasma concentrations of L in Group 1
(grading positive/self-report positive) were 2.2 times greater
than among participants in Group 2 (grading positive/self-
Table 1. Demographics, health and lifestyle characteristics of participants in this
investigation.
Variables (n = 4,423) Mean ± SD or n (%)
Age (years) 61.36 ± 8.19
50–64 2888 (65.3%)
65–74 1174 (26.5%)
75+ 361 (8.2%)
Sex (Female) 2378 (53.8%)
Education level
Primary/none 944 (21.4%)
Secondary 1861 (42.1%)
Third level 1616 (36.5%)
BMI (kg/m2) 27.13 ± 8.13
Smoking status*
Never 2036 (46.0%)
Past 1728 (39.1%)
Current 659 (14.9%)
Plasma L, µmol/L 0.2072 ± 0.128
Plasma Z, µmol/L 0.0562 ± 0.047
Family history of AMD*
Don’t know 423 (9.6%)
No 3769 (85.2%)
Yes 231 (5.2%)
Self-reported AMD* 65 (1.5%)
Grading-confirmed AMD 288 (6.5%)
Early AMD 273 (6.2%)
Late AMD 15 (0.34%)
Supplement use* 102 (2.3%)
Data displayed are mean ± standard deviation (SD) for interval data and
percentages for categorical data: Variables, variables analyzed in the study;
n, number of participants; Education level, highest level of education (primary/
none, secondary, and third level); BMI, body mass index; Smoking status, never
(non-smoker), past smoker and current smoker; Plasma lutein (L) and total
zeaxanthin (Z), concentrations measured by high performance liquid chroma-
tography; Family history of AMD, % of participants self-reporting family history
of age-related macular degeneration; Self-reported AMD, % of participants
that self-reported a doctor diagnosis of AMD; Grading-confirmed AMD, % of
participants with grading-confirmed AMD, retinal photographs were graded by
a certified grader using a modified version of the International Classification
and Grading System for AMD, thereby establishing such a diagnosis;
Supplement use, use of supplements containing either L and/or Z and/or
MZ;* Self-reported.
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report negative) and 2.3 times greater than participants in
Group 4 (grading negative/self-report negative). Also, plasma
concentrations of L in Group 3 (grading negative/self-report
positive) were 1.5 times greater than among participants in
Group 2 (grading positive/self-report negative) and 1.6 times
greater than participants in Group 4 (grading negative/self-
report negative). Further, our results also strongly suggest
that these findings are attributable to greater use of a supple-
ment containing at least one of the three macular carote-
noids among those who believe (correctly or incorrectly) that
they suffer from AMD. With respect to plasma Z concentra-
tions, only Group 1 (grading positive/self-report positive)
had significantly higher concentrations of Z when compared
with the other groups. One possible explanation for this
observation could rest on the fact that this group consisted
solely of participants correctly reporting doctor-diagnosed
AMD, and therefore more likely (perhaps) to secure a
recommendation to consume a supplement that included at
least two of the three macular carotenoids (including Z) and
not merely a L-containing formulation. Importantly, the data
reported herein were recorded as part of Wave 1 of TILDA
(between 2009 and 2011), a period when supplementation
with macular pigment’s constituent carotenoids was already
in widespread use for the purpose of managing AMD, in
spite of the fact that the findings of AREDS 2 were not
published until 2013.27
Of the 288 participants with grading-confirmed AMD, 264
participants (92%) were unaware that they were afflicted with
the condition (Group 2), an unsurprising finding given that
patients with non-advanced AMD are typically unaware of
their condition because vision is only profoundly affected if
and when the disease progresses to the advanced stage28 and
given that 273 participants (95%) with grading-confirmed
AMD in this study suffered from the early (non-advanced)
form of the condition.5
With respect to epidemiologic studies reporting on serum
concentrations of L and/or Z, it would appear that some cross-
sectional studies may now need to be re-interpreted in light of
our novel findings. For example, reference values for plasma
caroteniods published after 1999may now need to be revisited.-
29 One could exclude participants with AMD, participants who
believe that they suffer from AMD, participants with a family
history of AMD and also participants who use a supplement
containing at least one of the three macular carotenoids, for the
purposes of generating reference values, but thismeasure would
necessarily render the sample non-representative of the popu-
lation at large and would exclude a sub-population that is of
particular interest. Another concern arising from our findings
rests on the interpretation of cross-sectional epidemiologic
studies attempting to investigate a possible association between
macular pigment’s constituent carotenoids and the prevalence
of AMD. Such studies are, in any case, inherently problematic,
not least becausemacular pigment’s constituent carotenoids are
intracellular compounds and AMD (whether non-advanced or
advanced) results in loss of photoreceptors and their axons.30,31
In other words, the principal shortcoming of cross-sectional
studies in this respect rests not only on the impossibility of
determining causality, but also because it is very likely that
AMD causes loss of “housing” to accommodate macular pig-
ment (and, therefore, a lack of macular pigment in association
0.5
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Figure 2. Mean plasma concentrations of lutein and total zeaxanthin of subgroups in this investigation. Plasma lutein and zeaxanthin concentrations measured by high
performance liquid chromatography. Group 1 (n = 24): grading-confirmed AMD in association with self-reported AMD; Group 2 (n = 264): grading-confirmed AMD in the
absence of self-reported AMD; Group 3 (n = 41): grading-confirmed absence of AMD in association with self-reported AMD; Group 4 (n = 4094): grading-confirmed absence
of AMD in association with self-reported absence of AMD. Grading-confirmed AMD, retinal photographs were graded by a certified grader using a modified version of the
International Classification and Grading System for AMD; Self-reported AMD, participants were asked whether a doctor had diagnosed them with AMD.
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with the disease is probably the result [and not the cause] of the
disease)32; accordingly, cross-sectional studies investigating
possible relationships between AMD and macular pigment are
subject to greater confounding than those investigating possible
relationships between AMD and serum concentrations of
macular pigment’s constituent carotenoids. Nevertheless, and
with full appreciation of the limitations of associative studies,
there have been no less than 12 cross-sectional reports attempt-
ing to investigate the relationship between serum concentra-
tions of macular pigment’s constituent carotenoids and the risk
for AMD (see Table 2).20–23,33–40 Further, and notwithstanding
the fact that many of these cross-sectional studies were per-
formed in the pre-AREDS 2 era, it should be appreciated that
lutein-containing supplements were commercially available
since 1999,41 and since that date their use grew substantially
as a result of widespread dissemination of their putative
benefits.42–48 Meaningful comment on any such relationship
should be predicated, therefore, on population-based studies
where data were recorded pre-1999 and to subsequent popula-
tion-based studies where the use of carotenoid-containing sup-
plements was recorded and appropriately factored into
analyses. Three20-22 of four20-22,35 (75%) population-based stu-
dies using data recorded pre-1999 found an inverse relationship
between AMD and serum concentrations of L and/or Z, and
this compares with none of one38 (0%) population-based stu-
dies utilizing data recorded after 1999 where supplement use
was recorded and factored into analyses (see Table 2).
The findings reported herein also have implications for the
debate regarding the appropriateness of introducing a screen-
ing program for non-advanced AMD.49 A screening program
can only be justified when there is a proven intervention for
subjects with pre-disease or asymptomatic disease, and who
are identified by use of a test that is sensitive (i.e. few false
negatives) and specific (i.e. few false positives).50 Accordingly,
non-advanced AMD would appear to be an ideal candidate
for a screening program, especially given our findings that
awareness of the condition is associated with supplement use
and consequentially increased plasma concentrations of L.
Indeed, a screening program for non-advanced AMD could
avail of existing infrastructures (community-based cameras,
centralized reading center, etc.), which had been shown to be
efficacious and cost-effective for the purposes of screening for
diabetic retinopathy51 (although it would need to be extended
to the entire population aged 50 years and older, which
represents a substantially greater number of participants
than the diabetic population).
Further, and beyond risk-reduction for disease progression
and visual loss, it is important to emphasize that antioxidant
supplements also confer visual benefits in patients with non-
advanced AMD in the short- and medium-term, and are
therefore not solely aimed at risk reduction of ultimate disease
progression.19 Indeed, in the recent study by Akuffo et al,
antioxidant supplementation in patients with non-advanced
AMD over a 24-month period was shown to enhance vision in
non-advanced AMD patients (a condition traditionally asso-
ciated with progressive visual loss), reflected in statistically
significant improvements in contrast sensitivity, glare disabil-
ity, photostress recovery, and reading speed.19 These improve-
ments are not trivial, and improve quality of life in patients
with non-advanced AMD, as well as reducing the risk of
adverse and vision-related insults to health (e.g. falls and hip
fracture).52
Accordingly, establishment of a screening program would
facilitate appropriate disease-retarding17, sight-saving17 and
Table 2. Summary of cross-sectional studies designed to investigate a possible relationship between age-related macular degeneration and serum concentrations of
macular pigment’s constituent carotenoids.
First Author, publication
year
Period of data
collection
Sample
size
Type of
study
Correlates under
investigation
Use of L and/or, Z and/or MZ
containing supplements Principal finding
EDCC Study Group, 199323 1986-1990 968 C-C Serum L and Z (combined) Data not recorded Inverse relationship with
serum L and Z
Mares-Perlman et al., 199533 1988-1990 334 C-C Serum L and Z (combined) Data not recorded No relationship identified
Mares-Perlman et al., 200121 1988-1994 8,222 P-B Serum L and Z (combined) Data not recorded Inverse relationship with
serum L and Z**
Sanders et a., 199334 130 C-C Serum L Data not recorded No relationship identified
Moeller et al., 200635 1994-98 & 2001-04*| 1,787 P-B Serum L and Z Data not factored No relationship identified
Gale et al., 200322 1996-1997 380 P-B Serum L and Z Data not recorded Inverse relationship with
serum Z
Delcourt et al., 200620 1996-1997 640 P-B Serum L and Z Data not recorded Inverse relationship with
serum L and Z
Dasch et al., 200536 2001-2003 910 C-C Serum L and Z Data recorded and factored
into analyses
No relationship identified
Simonelli et al., 200237 94 C-C Serum L and Z (combined) Data not recorded No relationship identified
Michikawa et al., 200938 2005-2006 722 P-B Serum L and Z (combined) Data not recorded No relationship identified.
Cardinault et al., 200539 55 C-C Serum L and Z Data not recorded No relationship identified
Zhou et al., 201140 2007-2008 263 C-C Serum L and Z Data recorded and factored
into analyses
Inverse relationship with
serum Z
Publications organized by publication date in the absence of authors reporting period of data collection; solid line indicates the year (1999) that lutein-containing
supplements were commercially available; principal finding is italicized when an inverse relationship is reported. EDCC Study Group, Eye Disease Case-Control Study
Group; Type of study: C-C, case-control study; P-B, population-based study; Correlates under investigation: serum lutein (L) and total zeaxanthin (Z), concentrations
measured by high performance liquid chromatography (HPLC); Use of L and/or, Z and/or MZ supplements: Data not recorded; supplement data not collected
during study visit; Data not factored into analyses, supplement data was collected but not used in analysis between age-related macular degeneration subjects and
control subjects; Data recorded and factored into analyses, data of supplement use was collected during study and factored into analyse, exclusion of subjects
consuming supplements, or confirmation that none of the subjects consumed supplements; *Serum concentrations of L and Z were collected in 1994-1998,
however data on supplement use was collected 2001–2004; **inverse relationship, though marginal.
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vision-optimizing19 nutritional interventions to be offered to
subjects who would otherwise be unaware that they are
afflicted with the non-advanced form of AMD, and would
likely be justified by the financial savings accruing from early
detection of disease.
The principal strengths of this study rest on its large popu-
lation-based sample size (n = 4,423). Also, and somewhat
uniquely, this cohort represents a racially homogeneous sample
(99% were white and Irish born). However, this study also has
limitations, including the fact that the TILDA study sample
excluded individuals who were institutionalized (e.g. living in
nursing homes) and, also, individuals aged 75 years and older
were underrepresented in the sample.24 Although diurnal var-
iation of serum concentrations of L and Z has been reported to
be negligible, there are seasonal effects for serum concentra-
tions of L and Z, which differs between individuals.53
Moreover, dietary data would have enriched the analysis and
interpretation of our data, given that we were studying com-
pounds, which are entirely of dietary origin.
In conclusion, we report that a belief that one suffers from
AMD (irrespective of whether that belief is founded or
unfounded) is associated with supplement use and conse-
quentially higher plasma concentrations of L. This finding
represents a hitherto unappreciated confounding variable for
interpretation of cross-sectional epidemiologic studies inves-
tigating relationship between AMD and macular pigment’s
constituent carotenoids.
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